

EN
P-001626/2024
Answer given by Ms Kyriakides
on behalf of the European Commission
(9.10.2024)

In 2022 the Commission purchased 334,540 doses of the MVA-BN vaccine (called Jynneos in the United States and Imvanex in the EU) and donated those to the Member States to respond to the global outbreak of mpox in Europe.

The Commission also concluded framework contracts under the Joint Procurement Agreement (JPA) that allow participating countries to purchase up to 2 million doses of vaccine until the end of 2024 and 10 million courses of the therapeutic Tecovirimat SIGA until mid-2026. The Commission is currently in discussions with the JPA participant countries and the manufacturer Bavarian Nordic to conclude a new vaccine framework contract.

Imvanex is the only vaccine authorised at Union level for adult immunisation against mpox. The European Commission issued a decision extending the indication of use for Imvanex to include adolescents from 12 to 17 years of age on 19 September 2024. Tecovirimat SIGA is the only medicine authorised at EU level for treatment of mpox in adults and children weighing at least 13 kg.

Following the World Health Organisation (WHO) declaration of a Public Health Emergency of International Concern on 14 August 2024, the Commission donated 215,420 vaccine doses to Africa via the Africa Centres for Disease Control and Prevention. To date, 200,000 of these doses have been delivered to the Democratic Republic of Congo. The Commission is also co-ordinating the response by the EU and Member States in a Team Europe approach where Member States have so far committed to donating approximately 360,000 additional doses to Africa as soon as an agreement is reached on allocation and acceptance of these doses by recipient countries.